Nanjing Hicin Pharmaceutical Co., Ltd. is a prominent high-tech private pharmaceutical enterprise established in 2003 and headquartered in the Nanjing Economic and Technological Development Zone in Jiangsu Province, China. The company operates as an integrated enterprise specializing in pharmaceutical research and development, manufacturing, and marketing. Over the years, Nanjing Hicin Pharmaceutical has expanded its presence significantly within the pharmaceutical industry, culminating in its successful listing on the ChiNext board of the Shenzhen Stock Exchange in January 2017.
The enterprise is built upon a foundation of scientific innovation and rigorous quality control, employing a dedicated workforce of professionals spanning pharmacy, medicine, chemistry, and bioengineering. The company's operational framework spans multiple specialized subsidiaries and research facilities, enabling a comprehensive approach to chemical preparations, active pharmaceutical ingredients (APIs), and pharmaceutical intermediates.
Research and Development Capabilities
A core pillar of Nanjing Hicin Pharmaceutical Co., Ltd. is its robust commitment to research and development. The company maintains an expansive R&D center spanning thousands of square meters located within the Jiangsu Life Science and Technology Innovation Park. This facility houses advanced scientific instruments and is supported by a highly skilled team of researchers, scientists, and industry experts holding advanced degrees such as master's and doctoral qualifications.
The R&D division focuses on creating innovative chemical drugs, improving existing formulations, and conducting technical transfers. Through continuous scientific endeavors, the company has accumulated numerous intellectual property assets, including dozens of invention patents and a significant portfolio of new drug certificates authorized by regulatory authorities. The R&D team works closely with production facilities to ensure seamless translation of laboratory discoveries into scalable, high-quality commercial products.
Manufacturing Facilities and Infrastructure
Nanjing Hicin Pharmaceutical Co., Ltd. operates state-of-the-art manufacturing facilities designed and maintained in strict accordance with Good Manufacturing Practice (GMP) standards. The company's production infrastructure encompasses multiple specialized workshops dedicated to different dosage forms and categories:
- Sterile Lyophilized Powder Workshops: Equipped for the production of complex sterile injectable products.
- Small-Volume Injection Workshops: Dedicated to manufacturing various liquid injectables under stringent sterile conditions.
- Cephalosporin Workshops: Specialized areas dedicated exclusively to the production of cephalosporin-based lyophilized powders and formulations to prevent cross-contamination.
- Solid Dosage Form Workshops: Advanced production lines capable of producing tablets, capsules, and granules.
- API and Intermediate Production Bases: Supported by dedicated manufacturing subsidiaries such as Zhenjiang Dery Pharmaceutical Co., Ltd., which focus on synthesizing active pharmaceutical ingredients and chemical intermediates.
These facilities are engineered with advanced environmental controls, ensuring clean air management, dust suppression, and adherence to national environmental protection standards.
Products and Therapeutic Areas
Nanjing Hicin Pharmaceutical Co., Ltd. offers a diverse portfolio comprising over sixty representative commercial products spanning multiple major therapeutic categories. The company's product offerings cater to critical medical needs across several clinical domains:
Cardiovascular and Cerebrovascular System
The company produces specialized medications designed to manage cardiovascular and cerebrovascular conditions, supporting blood circulation and heart function. Key products include landiolol hydrochloride and other targeted agents used in acute and chronic cardiovascular management.
Diuretic Agents
Among its flagship preparations, the company manufactures torasemide-based products, such as torasemide for injection, widely utilized for managing edema and fluid overload associated with heart failure, renal impairment, and hepatic disease.
Anti-Infection and Antibiotic Products
To combat bacterial and microbial infections, Nanjing Hicin Pharmaceutical manufactures a range of cephalosporins and broad-spectrum antibiotics. Key offerings include cefuroxime sodium, ceftriaxone hydrochloride, cefepime hydrochloride for injection, and tigecycline, which play vital roles in hospital and clinical anti-infective therapy.
Digestive System Medications
The company provides advanced gastrointestinal treatments, including proton pump inhibitors and related formulations such as lansoprazole enteric-coated tablets, omeprazole sodium for injection, and other therapeutic agents designed to treat gastric ulcers, acid reflux, and related digestive disorders.
Endocrine and Metabolic Agents
Addressing metabolic conditions such as diabetes, the company produces oral hypoglycemic medications, including voglibose tablets, which assist in controlling postprandial blood glucose levels in patients with type 2 diabetes mellitus.
Immune Regulation and Other Therapeutic Areas
The product lineup also features adenosine monophosphate and related formulations utilized for immune modulation and supportive therapy, alongside specialized products for orthopedic care and other clinical specialties.
Quality Assurance and Regulatory Compliance
Quality management is deeply embedded in the operational philosophy of Nanjing Hicin Pharmaceutical Co., Ltd. The company maintains an independent and fully equipped Quality Assurance Department staffed by trained professionals who oversee every stage of the manufacturing lifecycle.
Rigorous analytical testing and continuous monitoring are applied to incoming raw materials, in-process intermediates, and finished products—both chemical preparations and APIs. The quality control laboratories are outfitted with sophisticated analytical instruments capable of performing high-precision assays, chromatographic separations, and microbiological testing to ensure absolute compliance with national and international pharmacopeia standards.
Furthermore, the company adheres strictly to national environmental protection regulations, integrating green manufacturing practices to minimize industrial waste and promote sustainable industrial development.
Global Reach and Market Presence
While serving the domestic healthcare market extensively through widespread distribution networks across various Chinese provinces and hospitals, Nanjing Hicin Pharmaceutical Co., Ltd. also engages in international trade. The company exports selected active pharmaceutical ingredients and finished pharmaceutical preparations—such as omeprazole sodium and cefepime hydrochloride—to numerous international markets, including countries across South Asia, South America, and Europe. Through continuous innovation, regulatory compliance, and strategic international partnerships, the company remains dedicated to advancing healthcare outcomes globally.
